Inoue M, Itoh H, Tanaka T, Chun T H, Doi K, Fukunaga Y, Sawada N, Yamshita J, Masatsugu K, Saito T, Sakaguchi S, Sone M, Yurugi T, Nakao K
Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):560-6. doi: 10.1161/01.atv.21.4.560.
Vascular endothelial growth factor (VEGF) has been recognized as an angiogenic factor that induces endothelial proliferation and vascular permeability. Recent studies have also suggested that VEGF can promote macrophage migration, which is critical for atherosclerosis. We have reported that VEGF is remarkably expressed in activated macrophages, endothelial cells, and smooth muscle cells within human coronary atherosclerotic lesions, and we have proposed the significance of VEGF in the progression of atherosclerosis. To clarify the mechanism of VEGF expression in atherosclerotic lesions, we examined the regulation of VEGF expression by oxidized low density lipoprotein (Ox-LDL), which is abundant in atherosclerotic arterial walls. A recent report has revealed that peroxisome proliferator-activated receptor-gamma (PPARgamma) is expressed not only in adipocytes but also in monocytes/macrophages and has suggested that PPARgamma may have a role in the differentiation of monocytes/macrophages. Furthermore, 9- and 13-hydroxy-(S)-10,12-octadecadienoic acid (9- and 13-HODE, respectively), the components of Ox-LDL, may be PPARgamma ligands. Therefore, we investigated the involvement of PPARgamma in the regulation of VEGF by Ox-LDL. PPARgamma expression was detected in human monocyte/macrophage cell lines, human acute monocytic leukemia (THP-1) cells, and human coronary artery endothelial cells (HCAECs). Ox-LDL (10 to 50 microg/mL) upregulated VEGF secretion from THP-1 dose-dependently. VEGF mRNA expression in HCAECs was also upregulated by Ox-LDL. The mRNA expression of VEGF in THP-1 cells and HCAECs was also augmented by PPARgamma activators, troglitazone (TRO), and 15-deoxy-(12,14)-prostaglandin J(2) (PGJ2). In contrast, VEGF expression in another monocyte/macrophage cell line, human histiocytic lymphoma cells (U937), which lacks PPARgamma expression, was not augmented by TRO or PGJ2. We established the U937 cell line, which permanently expresses PPARgamma (U937T). TRO and Ox-LDL augmented VEGF expression in U937T. In addition, VEGF production by THP-1 cells was significantly increased by exposure to 9-HODE and 13-HODE. In conclusion, Ox-LDL upregulates VEGF expression in macrophages and endothelial cells, at least in part, through the activation of PPARgamma.
血管内皮生长因子(VEGF)已被公认为一种诱导内皮细胞增殖和血管通透性的血管生成因子。最近的研究还表明,VEGF可促进巨噬细胞迁移,这对动脉粥样硬化至关重要。我们曾报道,VEGF在人类冠状动脉粥样硬化病变内的活化巨噬细胞、内皮细胞和平滑肌细胞中显著表达,并提出了VEGF在动脉粥样硬化进展中的意义。为阐明VEGF在动脉粥样硬化病变中表达的机制,我们研究了氧化型低密度脂蛋白(Ox-LDL)对VEGF表达的调控,Ox-LDL在动脉粥样硬化动脉壁中含量丰富。最近的一份报告显示,过氧化物酶体增殖物激活受体γ(PPARγ)不仅在脂肪细胞中表达,还在单核细胞/巨噬细胞中表达,并提示PPARγ可能在单核细胞/巨噬细胞的分化中起作用。此外,Ox-LDL的成分9-羟基-(S)-10,12-十八碳二烯酸和13-羟基-(S)-10,12-十八碳二烯酸(分别为9-HODE和13-HODE)可能是PPARγ配体。因此,我们研究了PPARγ在Ox-LDL对VEGF调控中的作用。在人单核细胞/巨噬细胞系、人急性单核细胞白血病(THP-1)细胞和人冠状动脉内皮细胞(HCAECs)中检测到PPARγ表达。Ox-LDL(10至50μg/mL)剂量依赖性地上调THP-1细胞的VEGF分泌。Ox-LDL也上调了HCAECs中VEGF mRNA的表达。PPARγ激动剂曲格列酮(TRO)和15-脱氧-(12,14)-前列腺素J2(PGJ2)也增强了THP-1细胞和HCAECs中VEGF的mRNA表达。相反,在另一种缺乏PPARγ表达的单核细胞/巨噬细胞系人组织细胞淋巴瘤细胞(U937)中,TRO或PGJ2并未增强VEGF表达。我们建立了稳定表达PPARγ的U937细胞系(U937T)。TRO和Ox-LDL增强了U937T细胞中VEGF的表达。此外,THP-1细胞暴露于9-HODE和13-HODE后,VEGF产生显著增加。总之,Ox-LDL至少部分通过激活PPARγ上调巨噬细胞和内皮细胞中VEGF的表达。